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At a Glance Commentary 
Scientific Knowledge on the Subject: 
Pulmonary non-tuberculous mycobacterial infection (pNTM) is increasingly 
common and associated with a high mortality, although the clinical course is 
unpredictable. The factors predisposing towards the development of disease 
and its subsequent progression remain unclear. Impaired immune responses 
have been reported in individuals with pNTM but data are limited and 
inconsistent. 
What This Study Adds to the Field: 
The expression of many genes mediating cellular immunity was depressed in 
pNTM disease, including IFNG, which correlated negatively with markers of 
disease severity. Mortality was associated with  the expression of transcripts 
related to the innate immune response and inflammation, whereas transcripts 
relating to T and B cell function were associated with improved survival. 
These findings suggest that pNTM is associated with an altered immune 
response which may both contribute to the development of disease as well as 
its severity. The expression of genes identified in this study warrant further 
investigation as potential markers of disease activity and suggest targets for 
potential therapeutic intervention. 
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This article has an online data supplement, which is accessible from this 
issue's table of content online at www.atsjournals.org
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Abstract 
Rationale: The factors predisposing towards the development of pulmonary 
non-tuberculous mycobacterial disease (pNTM) and influencing disease 
progression remain unclear. Impaired immune responses have been reported 
in individuals with pNTM but data are limited and inconsistent. 
Objectives: To use gene expression profiling to examine the host response 
to pNTM. 
Methods: Microarray analysis of whole blood gene expression was performed 
on 25 subjects with pNTM and 27 uninfected controls with respiratory disease. 
Gene expression results were compared to phenotypic variables and survival 
data. 
Measurements and Main Results: Compared with uninfected controls, 
pNTM was associated with down-regulation of 213 transcripts enriched for 
terms related to T cell signalling including IFNG. Reduced IFNG expression 
was associated with more severe CT changes and impaired lung function. 
Mortality was associated with  the expression of transcripts related to the 
innate immune response and inflammation, whereas transcripts related to T 
and B cell function were associated with improved survival. 
Conclusions: These findings suggest that pNTM is associated with an 
aberrant immune response which may reflect an underlying propensity to 
infection, or result from NTM infection itself. There were important differences 
in the immune response associated with survival and mortality in pNTM. 
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Abstract word count: 193/250 words. 
Key words: Nontuberculous mycobacteria, gene expression profiling 
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Introduction 
Pulmonary non-tuberculous mycobacterial disease (pNTM) is an increasingly 
common and challenging infection. Whilst ubiquitous in the environment, 
disease usually occurs in the context of an existing pulmonary disease such 
as bronchiectasis or COPD, although in a subgroup of patients disease 
occurs in the absence of any known risk factors. The disease is associated 
with a high mortality ranging between 12.5% to 41.1% at five years (1-5). The 
clinical course of disease is variable and unpredictable, whilst some 
individuals develop progressive disease, some may remain stable without 
treatment (1, 6, 7). The factors governing the acquisition of disease and its 
subsequent clinical course are poorly understood. 
Disseminated NTM disease occurs in the context of immunodeficiency such 
as AIDS or inherited and acquired defects of the IFN-γ/IL-12 pathway, and 
several studies have also demonstrated functional defects in the host immune 
response of subjects with pNTM (8-13). A recent study employing exome 
sequencing revealed an excess of variants affecting genes implicated in the 
immune response in subjects with pNTM compared with both the control 
population and unaffected family members (14). These findings suggest that 
defective immune responses may play a role in predisposing individuals to 
pNTM. The aims of this study were to investigate the host response to pNTM 
using global gene expression profiling of peripheral blood and to explore the 
relationship between gene expression and clinical outcomes. 
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Methods 
Individuals with pNTM were recruited from the Royal Brompton Hospital and 
Chelsea and Westminster Hospital between September 2012 and November 
2013. All participants met ATS 2007 criteria and were unanimously deemed to 
have active disease requiring treatment by two clinicians with expertise in 
pNTM (authors ML and RW). Control subjects with respiratory disease 
(bronchiectasis or COPD) but no radiological or microbiological evidence of 
mycobacterial disease were recruited from the same departments. Written 
consent was gained from all participants and the study was approved by the 
local Research Ethics Committee (reference 12/LO/1034). 
Participants underwent clinical assessment and pulmonary function testing. 
Peripheral blood was taken for RNA extraction and clinical testing and 
spontaneously expectorated sputum was collected for phenol auramine 
microscopy and bacterial, mycobacterial and fungal cultures. If not performed 
within the previous six months, a HRCT was performed. For NTM cases CT 
scoring was performed by a specialist radiologist blinded to clinical details as 
described previously (15) and a composite score calculated by summing the 
scores for individual features. Further methods are provided in the online data 
supplement. 
Gene expression analysis 
Peripheral blood was collected into PAXgene RNA tubes (Becton, Dickinson 
and Company, NJ, USA) and RNA extracted using the PAXgene Blood RNA 
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Kit (PreAnalytiX, Hombrechtikon, Switzerland). Extracted RNA was amplified 
to complementary DNA using the Ovation Pico WTA System V2 (NuGEN 
Technologies, San Carlos, USA), then cDNA was fragmented and labelled 
using the Encore Biotin Module (NuGEN Technologies) and immediately 
hybridised to Affymetrix Human Gene 1.1 ST array plates and scanned using 
the GeneTitan instrument (Affymetrix, Santa Clara, USA). Samples were 
randomised prior to amplification and again prior to fragmentation, labelling 
and hybridisation. 
Outliers were identified using the arrayQualityMetrics package (16) in the R 
environment version 3.1.2 and removed. Raw probe level data from .CEL files 
passing quality control were summarised, quantile normalised and log2 
transformed using the Affymetrix Power Tools package. Expression data were 
re-imported into R where low-expressed and unannotated probes were 
removed and all downstream analyses performed. 
Differentially expressed genes were identified using Significance Analysis of 
Microarrays (SAM) (17) applying a false discovery rate (FDR) of 5% for 
significance. Gene ontology analyses were performed using the WebGestalt 
tool (http://www.webgestalt.org) using the Gene Ontology Consortium (GO) 
and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. All 
expressed genes were used as the reference set, an adjusted P value of 0.05 
was deemed significant. 
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Weighted Gene Co-expression Gene Network Analysis (WCGNA) was 
performed using the WGCNA package (18) with the default recommended 
parameters. All expressed genes were entered into the analysis, however 
only genes with a connectivity in the highest tertile were used to construct the 
topological overlap matrix. 
Correlation between gene (or gene module) expression and clinical variables 
was performed using the Pearson or Spearman correlation for continuous 
variables according to their distribution, and polyserial correlation for 
categorical variables. The t-test and analysis of variance (ANOVA) were used 
to compare expression values between groups. The log-rank test was used to 
compare differences in survival curves. 
Results 
A total of 52 subjects (25 pNTM cases and 27 controls) matched for age, sex 
and ethnicity were studied. Clinical characteristics of the study cohort are 
detailed in Table 1 with further details provided in Tables E2 and E3 of the 
online data supplement. The proportion of subjects with a diagnosis of 
bronchiectasis was lower (although not significantly so) in the group of NTM 
cases due to the inclusion of subjects with “Lady Windermere’ syndrome. 
These individuals (N=7) had no underlying lung disease prior to their NTM 
infection, although at the time of enrolment bronchiectasis was present in all 
subjects on HRCT. 
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Gene expression and NTM disease 
A total of 213 transcripts were identified as differentially expressed between 
cases and controls with a FDR of 5% (for full list see Table E4 in the online 
data supplement and Figure E1). All transcripts were down-regulated in pNTM 
disease. The top 25 genes with the highest fold change are detailed in Table 
2. 
One of the top differentially expressed genes in pNTM cases compared with 
controls was interferon gamma (IFNG) (Figure 1). Interferon gamma (IFN-γ) is 
the primary effector cytokine of the Th1 pathway which plays a vital role in 
mycobacterial immunity. In light of this it is notable that other differentially 
expressed genes included Nuclear factor of activated T cells 2 (NFATC2), 
Cytotoxic and regulatory T cell molecule (CRTAM) and X-C Motif Chemokine 
Ligand 1 and 2 (XCL1, XCL2). NFATC2 encodes NFATc2, a member of the 
nuclear factor of activated T cells (NFAT) family of transcription factors. 
NFATc2 has been shown to be an in vitro regulator of both IFN- γ (19, 20) 
and TNF-α (21, 22) release. The product of CRTAM also promotes IFN-γ 
release from CD8+ T-cells (23-27) and NK cells (28, 29).  XCL2 encodes a 
chemokine which is chemotactic for CD8+ and CD4+ T-cells (30, 31) and its 
homologue, XCL1, encodes a chemokine associated with the Th1 response, 
the silencing of which has been shown to lead to reduced IFN-γ production 
and disordered granuloma formation in TB infected mice (32, 33). 
Gene ontology (GO) analysis of the set of differentially expressed transcripts 
revealed enrichment for one biological process, “Negative regulation of alpha-
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beta T cell proliferation” (enrichment ratio 36.01 adjusted P = 0.049) and a 
further ten GO cellular components. Additionally KEGG analysis revealed 
enrichment for the pathway “T cell receptor signaling” (enrichment ratio 6.12, 
adjusted P < 0.001), with nine genes in the pathway (IFNG, AKT3, CD247, 
MAPK9, CBLB, NFATC2, ICOS, RASGRP1 and ITK) being significantly under-
expressed in pNTM cases. Full details are given in Table E5 of the online data 
supplement. 
To examine the influence of systemic steroid use and NTM treatment on the 
observed difference in gene expression, multiple linear modelling was 
performed using these as additional explanatory variables in addition to NTM 
disease. The expression of 168 of the 213 genes (79%) remained significantly 
associated with NTM disease (see Table E6 in the online data supplement). 
The 213 transcripts were compared with the 380 gene ‘meta-signature’ of 
active tuberculosis identified by Blankley et al. (34). There was an overlap of 
only nine genes (CDK5RAP2, EPHA4, FAIM3, FCRL3, GPR183, GZMK, KLF12, 
NELL2 and SMA4), most of which were also downregulated in tuberculosis 
except CDK5RAP2 and SMA4 which showed increased expression. 
Comparison with studies of sarcoidosis, another granulomatous disease, 
revealed that 11 of the 213 transcripts (AKT3, CBLB, CCND2, CD247, ICOS, 
IFNG, IL2RB, ITK, MAPK9, NFATC2 and RASGRP1) are also present in the 
31-gene sarcoid signature described by Zhou et al. (35) representing 
significant (P < 0.001) enrichment. However, none of the 20 genes in the 
experimentally derived ‘unbiased’ signature from this study were present and 
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there was little or no overlap with other reported gene signatures in 
sarcoidosis (36, 37). 
In order to identify modules associated with pNTM, WGCNA was performed 
using all 13,360 expressed transcripts from the 52 subjects resulting in 10 
modules being identified (detailed in Table E7 and E8 of the online data 
supplement). Three modules showed significantly (P ≤ 0.05) different 
expression in pNTM cases compared to controls. These were enriched for 
multiple GO terms including those relating to T cell selection, differentiation, 
activation and signalling, and others associated with IFN-γ activity such as 
‘Natural killer (NK) cell mediated cytotoxicity’, ‘Antigen processing and 
presentation’, and ‘MHC class II protein complex’ (Table 3). In all cases the 
expression of genes within each module was lower in subjects with NTM 
disease. Of the 213 genes identified to be differentially expressed in pNTM 
cases compared to controls, 114 (53.5%) were present in one of the three 
modules that showed association with pNTM. 
IFNG expression and clinical outcomes 
Given the essential role of IFN-γ in the immune response to mycobacteria, the 
relationship between IFNG expression in pNTM cases and clinical variables 
was explored further. 
The expression of IFNG was significantly negatively correlated with several 
measures of lung function including FEV1 % predicted (Pearson’s r = 0.43 P = 
0.05), FVC % predicted (Pearson’s r = 0.51 P = 0.019) and TLC % predicted 
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(Pearson’s r = 0.48 P = 0.016). No significant correlations however were seen 
for transfer factor for carbon monoxide (TLCO) or the transfer factor corrected 
for alveolar volume (KCO). 
Expression of IFNG was strongly negatively correlated with combined CT 
score (Figure 2a, Pearson’s r = -0.53, P = 0.007). When individual CT 
features were examined (see Figure E2 in the online data supplement), IFNG 
expression was significantly lower in the presence of moderate or severely 
extensive bronchiectasis compared with a limited extent (P = 0.017 and P = 
0.029 respectively). 
In addition IFNG expression was associated with other markers of disease 
severity: it was positively correlated with serum albumin (Spearman’s ρ = 
0.50, P = 0.011), and negatively correlated with CRP (Spearman’s ρ = -0.42 P 
= 0.034) and neutrophil count (Pearson’s r = -0.52 P = 0.007). Interestingly, 
IFNG was also negatively correlated with time since diagnosis (Figure 2b, 
Spearman’s ρ -0.60 P = 0.005) although there was no correlation between the 
combined CT score and disease duration (Spearman’s ρ 0.24 P = 0.287). 
No significant differences were seen in mean IFNG expression between 
survivors and non-survivors, although when subjects were dichotomised into 
low and high IFNG expression there was a trend towards reduced survival in 
the low expression group. This however did not reach significance (log-rank 
test P = 0.06). 
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For disease control subjects, no significant associations between any 
measures of lung function or markers of disease severity and IFNG 
expression were observed (see table E9 in the online data supplement), 
suggesting the changes were specific to NTM disease and not merely due to 
disease severity in general. 
Gene expression and survival in NTM disease 
Survival data was available for 24 of the pNTM cases who had a mortality rate 
of 33% (8 deaths) during the study. No deaths were observed in the control 
group. Survival analysis was performed on these 24 cases using SAM with an 
FDR of 5%, 215 genes were found to show association with decreased 
survival and 1,131 genes with increased survival. The top enriched GO terms 
in relation to survival are given in Table 4 (for full results of the analysis 
please see Tables E10-12 and Figure E3 in the online data supplement). 
The top genes most strongly associated with reduced survival included genes 
forming part of the inflammasomes (Absent in melanoma 2 [AIM2], Caspase 
1 [CASP1] and NLR family CARD domain containing 4 [NLRC4]) or related to 
them (Caspase 4 [CASP4] and caspase recruitment domain family member 16 
and 17 [CARD16, CARD17]). The set of genes associated with reduced 
survival was enriched for 50 GO terms, many of which were related to the 
innate immune response and inflammation, including the IPAF and AIM2 
inflammasome complexes. Additionally the genes were enriched for six KEGG 
pathways including “Toll-like receptor signaling pathway”. 
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The top genes most strongly associated with increased survival included CD4, 
the T-helper cell co-receptor; CD28, a co-receptor which mediates T cell 
activation; and IL2RB, the beta subunit of the receptor for interleukin 2 which 
plays a key role in the regulation of lymphocyte proliferation and activation, 
and is also of importance in NK cell function through its roles as a subunit of 
the interleukin 15 receptor. The set of genes associated with improved 
survival was enriched for 26 GO terms, the majority of which were related to T 
cell and B cell function, and four KEGG pathways including “Antigen 
processing and presentation”. 
WGCNA was repeated focussing only on the pNTM cases in order to 
investigate disease survival. Nine modules were identified, three of which 
showed significant differential expression in non-survivors compared with 
survivors (Table 5 and Tables E13 and E14 of the online data supplement). Of 
the 215 genes associated with reduced survival by SAM, 74 (34.6%) were 
present in either the ‘white’ or ‘grey60’ modules, whilst 666 (58.9%) of the 
1,131 genes associated with increased survival were present in the 
‘darkorange’ module. 
Of note is the enrichment of the grey60 module for the GO term “RAGE 
receptor binding”. RAGE (the receptor for advanced glycation endproducts) is 
a pattern recognition receptor which has been implicated in neutrophilic 
inflammation in tuberculosis (38, 39). Whilst grey60 module itself was not 
significantly correlated with neutrophil count (Pearson’s r = 0.29, P = 0.152) 
many of the genes associated with RAGE were found to be significantly 
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correlated with neutrophilia (HMBG2: Pearson’s r 0.5 P = 0.011, S100A8: 
Pearson’s r 0.56 P = 0.003, S100A9: Pearson’s r 0.56 P = 0.003, S100A12: 
Pearson’s r 0.53 P = 0.006). 
Discussion 
In this study we have shown that NTM infection is associated with the 
differential expression of over two hundred genes. These were characterised 
by the reduced expression of many genes associated with cellular immunity, 
some of which have previously been identified to be important in the host 
response to mycobacterial infection. One of the top differentially expressed 
genes was IFNG, which plays an essential role in antimycobacterial immunity. 
Not only was IFNG expression lower in subjects with pNTM, but within this 
group reduced IFNG expression was significantly associated with more 
severe radiological disease and impaired lung function. There was also a 
trend towards an increased mortality in subjects with lower IFNG expression. 
These data are consistent with experimental evidence from in vitro studies 
which have demonstrated diminished Type 1 cytokine responses in patients 
with pNTM, showing reduced IL-12 (8-10) and IFN-γ (8-13) release after 
stimulation with both mitogen and NTM. These studies have employed 
varying methodologies (different cell types, stimuli and read-outs) and not all 
such studies have detected a difference in the immune response in subjects 
with pNTM (40-42). The evidence from this present study therefore provides 
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valuable unbiased evidence for an impaired IFN-γ response in subjects with 
pNTM, and is the first study to link this impairment with adverse clinical 
features. 
There is evidence that immunotherapy with IFN-γ may be beneficial in 
mycobacterial disease. Recombinant IFN-γ has been shown to improve 
sputum culture conversion in pulmonary TB infection (43) and has been used 
in refractory cerebral TB (21). Case reports have reported benefit from IFN-γ 
administration in NTM infection both in the presence (23, 25-27) and absence 
(28) of immunodeficiency. Two randomised controlled trials have been 
conducted in pNTM with one finding no benefit with inhaled IFN-γ (30) whilst 
the other observed a significant increase in treatment response with the 
addition of intramuscular IFN-γ (32). 
These results were supported by the networks analysis, which identified gene 
modules significantly under-expressed in pNTM which were enriched for 
several terms linked to IFN-γ activity. In light of reports of immunodeficiency 
due to anti-cytokine autoantibodies (44) it is also interesting to note that one 
module was enriched for genes regulating thymic T cell selection. 
The 215 genes associated with reduced survival were significantly enriched 
for multiple terms relating to innate immunity and pattern recognition 
receptors, including Toll-like receptor (TLR) signalling. Whilst TLR2 may have 
a protective role in murine models of NTM infection (45-49) and has been 
reported to display reduced expression in humans with pNTM (8) the pro-
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inflammatory response triggered by TLR2 may also be deleterious in NTM 
infection. The ‘rough’ variant of M. abscessus has been shown to trigger a 
hyper-inflammatory response via TLR2 signalling (50) which may play a role 
in the virulence associated with this phenotype (51). 
Interestingly, genes associated with inflammasome formation and pyroptosis 
were also overrepresented in the genes associated with reduced survival. 
Inflammasome activation has been reported in tuberculosis (52, 53) and has 
been proposed as a mechanism for the immune reconstitution inflammatory 
syndrome (IRIS) seen in HIV (54). To date only one report has demonstrated 
inflammasome activation by NTM (55) and little is known about their role in 
NTM infection. 
Network analysis identified an association between mortality and the 
expression of genes related to RAGE, including the proteins S100A8 and 
S100A9 which together form calprotectin, an important pro-inflammatory 
mediator (56). In a murine model, expression of RAGE in lung tissue has 
been shown to increase in response to TB infection, and gene knock-out 
caused an increase in weight loss and mortality (57). The expression of both 
S100A8 and S100A9 have been associated with neutrophilic inflammation in 
tuberculosis (38, 39) with the expression of S100A9 being suggested as a 
potential tuberculosis biomarker (58). 
Improved survival was associated with 1131 genes, which were enriched for 
several GO terms predominantly relating to T-cell differentiation and 
Page 19 of 59
Am
eri
ca
n J
ou
rn
l o
f R
es
pir
ato
ry 
Ce
ll a
nd
 M
ole
cu
lar
 B
iol
og
y 
Co
py
rig
ht 
© 
20
18
 A
me
ric
an
 Th
ora
cic
 S
oc
iet
y
16 
activation. Despite the trend towards higher expression in surviving NTM 
cases IFNG was not identified by SAM as being significantly associated with 
survival, although it was related to many of the enriched functional terms. 
Again the results of network analysis results were also supportive of these 
findings and identified a gene module associated with survival that was 
enriched for terms associated with T-cell development and signalling. 
Taken together, these findings suggest that pulmonary NTM disease is 
associated with the down-regulation of genes involved in the T-cell response, 
including IFNG, which is consistent with the results of in vitro studies in 
subjects with NTM infection. In subjects in whom disease has developed, the 
expression of genes involved in the T-cell response is associated with a better 
prognosis, perhaps reflecting the preservation of an appropriate response to 
NTM infection. Conversely a poor prognosis is associated with an up-
regulation of genes involved in innate immunity and inflammation, which may 
potentially mediate tissue damage and thus the progressive radiological 
changes observed. 
Infection with M. tuberculosis has been reported to down-regulate in vitro IFN-γ 
release (59) thus it is not clear whether the differences in gene expression 
represent a predisposing defect in host response or are a result of 
immunomodulation following NTM infection. The reduction in IFNG seen as 
disease duration increases may point towards the latter. Similarly the question 
remains as to whether the up-regulation of the innate immune response 
associated with poor survival is in some way contributory to pathogenesis, 
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perhaps due to excessive inflammation and tissue damage, or is merely a 
response to an increased burden of mycobacterial infection in those with 
severe disease. 
Pulmonary NTM disease is a heterogeneous condition containing a variety of 
clinical phenotypes, the most clinically relevant distinction being between 
fibro-cavitary and nodular-bronchiectatic disease. It is likely that the 
transcriptional response differs between these groups. Given the small 
sample size no comparison was made between different radiological patterns, 
however it is notable that IFNG expression strongly correlated with composite 
CT score, and was lower (although not significantly so) in individuals with 
severe cavitation. Another notable subgroup of individuals with NTM are those 
which demonstrate stable non-progressive disease in the absence of 
treatment (1, 6, 7) and it is also likely that their gene expression profiles differ 
to those seen in the individuals with active infection included in the present 
cohort. 
Several studies have been conducted examining gene expression in 
tuberculosis, and recently Blankley et al. characterised a 380 gene ‘meta-
signature’ of active tuberculosis showing consistent differential expression in 
at least nine datasets (34). There was little overlap between this signature and 
the genes associated with pNTM in the current study, and in contrast to pNTM 
gene expression in tuberculosis was characterised by an upregulation of IFN-
γ regulated genes (although not IFNG itself). This difference may relate to the 
infecting organism, or reflect a more appropriate host response to tuberculosis 
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in a generally younger population with fewer comorbidities as opposed to the 
potentially aberrant response seen in individuals with pNTM. There was 
however a point of similarity in that genes related to T-cells were consistently 
downregulated in both tuberculosis and pNTM. 
There was no overlap with experimentally derived expression signatures of 
sarcoidosis (35-37). However the 213 transcripts associated with pNTM were 
significantly enriched for genes in the 31-gene sarcoid signature described by 
Zhou et al. (35). These genes were chosen a priori as they are part of the T 
cell receptor, JAK STAT and cytokine-cytokine receptor signalling pathways 
implicated in sarcoidosis, and were able to differentiate sarcoidosis from 
controls with 82.2% accuracy. Eleven of these genes (35%) were also 
associated with pNTM in the current study, all of which were regulated in the 
same direction (down) in sarcoidosis. This is particularly interesting given the 
hypothesis that sarcoidosis may be driven by an aberrant immune response 
to mycobacterial antigens (60). 
This study has some limitations. The selection of subjects with definite active 
disease was necessary to provide a cohort with a well-defined phenotype but 
has limited the sample size and therefore the statistical power of the study. 
This may therefore limit the ability to generalise these findings to the wider 
NTM population. Even with such selection, the NTM study population remains 
highly heterogeneous, further limiting the power to detect differences in 
expression. This may explain the relatively modest differences in expression 
seen between groups in contrast to studies of a more homogenous population 
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such as those seen in tuberculosis. The use of inhaled or systemic steroids 
may have an effect on gene expression, however the proportions were similar 
between NTM cases and controls, and the exclusion of these subjects would 
necessitate the exclusion of most subjects with COPD, an important group at 
risk of NTM disease, and would further limit the ability to generalise the 
findings. 
Whilst being matched for basic demographics important phenotypic 
differences still remained between cases and controls, such as the high 
mortality seen in cases, systemic steroid use, and the treatment given for 
NTM. These differences may potentially contribute to the observed 
differences in gene expression. However, intervening to reduce the 
differences between groups by altering treatment would not have been 
feasible on ethical grounds, and the mortality in our cohort is in keeping with 
the known high mortality associated with NTM disease reported in other 
cohorts (1-5). Furthermore the expression of the majority of the differentially 
expressed transcripts (including IFNG) was significantly associated with NTM 
disease independent of systemic steroid use or NTM treatment. Similarly, 
several other factors were observed to be associated with survival (such as 
the presence of mycetoma) and the association seen between gene 
expression and survival may be therefore be confounded by these. 
Unfortunately the sample size precludes multivariate analyses to investigate 
these factors further. 
Conclusions 
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This is the first study of gene expression associated with NTM infection. The 
expression of many genes mediating cellular immunity was depressed in NTM 
disease, including IFNG, which correlated negatively with markers of disease 
severity. Whilst requiring further validation in independent cohorts, these 
findings are mechanistically plausible and consistent with previous 
experimental data. Mortality in NTM disease was associated with reduced 
expression of genes related to cellular immunity and increased expression of 
genes related to innate immunity, suggesting that disease progression may be 
driven by immune dysregulation. To our knowledge this is the first time the 
immune response to NTM has been linked to differences in disease 
outcomes. The expression of genes identified in this study warrant further 
investigation as potential markers of disease activity and suggest targets for 
potential therapeutic intervention. 
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Figure Legends 
Figure 1. Boxplots of IFNG expression in pNTM cases (grey) and controls 
(white). The central line, box boundaries and whiskers represent the median, 
first and third quartiles and the lowest and highest values lying within 1.5 
times the interquartile range, respectively. 
Figure 2 a) Expression of IFNG and combined CT score in NTM cases b) 
Expression of IFNG and duration of NTM disease. 
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Tables 
NTM cases 
N = 25 
Controls 
N = 27 
Age (years) 66.9 (±10.3) 65.4 (±7.5) 
Male sex (%) 9 (36%) 10 (37%) 
Ex- or current smoker (%) 14 (56%) 14 (52%) 
Underlying diagnosis (%) 
 COPD 7 (28%) 7 (26%) 
 Bronchiectasis 11 (44%) 20 (74%) 
 No underlying lung disease 7 (28%) 0 
FEV1 % predicted 48.64 (±31.42) 71.27 (±25.98) 
FVC % predicted 73.78 (±39.2) 102.25 (±20.87) 
Prophylactic antibiotics (%) 6 (24%) 8 (29%) 
Systemic corticosteroids (%) 3 (12%) 2 (7%) 
Inhaled corticosteroids (%) 12 (48%) 17 (63%) 
NTM treatment (%) 9 (36%) - 
NTM species 
 MAC 14 (56%) - 
 M. abscessus 4 (16%) - 
 M. xenopi 3 (12%) - 
 M. kansasii 2 (8%) - 
 M. malmoense 1 (4%) - 
 M. fortuitum 1 (4%) - 
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Table 1. Clinical characteristics of the study population. Continuous 
variables are stated as means ± standard deviations. COPD = chronic 
obstructive pulmonary disease, FEV1 = forced expiratory volume in 1 second, 
FVC = forced vital capacity, MAC = M. avium complex. 
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Rank 
Gene 
name 
Entrez ID 
Fold 
change 
d-
statistic 
Name 
1 FLJ45825 100505530 1.657 2.646 
uncharacterized LOC100505530 
2 GZMK 3003 1.61 2.857 granzyme K (granzyme 3; tryptase 
II) 
3 TARP 445347 1.609 2.619 TCR gamma alternate reading 
frame protein 
4 TARP 445347 1.609 2.619 TCR gamma alternate reading 
frame protein 
5 XCL2 6846 1.553 3.269 chemokine (C motif) ligand 2 
6 A2M 2 1.507 2.293 
alpha-2-macroglobulin 
7 CRTAM 56253 1.465 3.57 cytotoxic and regulatory T cell 
molecule 
8 PMS2P1 5379 1.453 4.053 postmeiotic segregation increased 2 
pseudogene 1 
9 FCRL3 115352 1.446 3.26 
Fc receptor-like 3 
10 PZP 5858 1.435 2.275 
pregnancy-zone protein 
11 TIGIT 201633 1.4 3.333 T cell immunoreceptor with Ig and 
ITIM domains 
12 PPIH 10465 1.393 2.897 peptidylprolyl isomerase H 
(cyclophilin H) 
13 AK5 26289 1.39 2.515 
adenylate kinase 5 
14 MUC12 10071 1.39 2.388 
mucin 12, cell surface associated 
15 IFNG 3458 1.382 2.622 
interferon, gamma 
16 FAHD2A 51011 1.364 3.021 fumarylacetoacetate hydrolase 
domain containing 2A 
17 SMA4 11039 1.361 3.602 
glucuronidase, beta pseudogene 
18 VSIG1 340547 1.356 2.784 V-set and immunoglobulin domain 
containing 1 
19 SAMD3 154075 1.35 2.367 sterile alpha motif domain 
containing 3 
20 XCL1 6375 1.348 2.247 
chemokine (C motif) ligand 1 
21 IL2RB 3560 1.347 2.242 
interleukin 2 receptor, beta 
22 PSPH 5723 1.339 2.232 
phosphoserine phosphatase 
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23 LDHB 3945 1.336 2.312 
lactate dehydrogenase B 
24 NELL2 4753 1.323 2.276 
NEL-like 2 (chicken) 
25 NFATC2 4773 1.322 2.804 
nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 
2 
Table 2. The top twenty five differentially expressed genes between 
pNTM cases and controls. Genes are ranked by fold-change, all displayed 
decreased expression in pNTM cases. 
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Module 
name 
Number 
of genes 
Correlation 
with NTM 
disease 
P value Relevant enriched GO terms 
Cyan 1,139 -0.31 0.02 
Thymic T cell selection 
T cell receptor signalling pathway 
Antigen processing and 
presentation 
Greenyellow 85 -0.32 0.02 
Cellular defence response 
Positive regulation of immune 
response 
T cell activation 
T cell receptor complex 
Natural killer cell mediated 
cytotoxicity 
CCR1 chemokine receptor binding 
Lightcyan 37 -0.27 0.05 
B cell activation 
B cell receptor complex 
MHC class II protein complex 
Table 3. Gene modules identified as significantly associated with NTM 
disease by WGCNA. 
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Top GO terms 
Enrichment 
ratio 
Adjusted 
P value 
Associated with decreased survival 
 response to other organism  GO:0051707 3.16 0.001 
 response to biotic stimulus  GO:0009607 3.00 0.001 
 activation of innate immune response  GO:0002218 5.56 0.001 
 detection of molecule of bacterial origin GO:0032490 30.71 0.001 
 regulation of innate immune response  GO:0045088 4.23 0.001 
Associated with increased survival 
 T cell selection  GO:0045058 6.19 1 x 104 
 lymphocyte differentiation  GO:0030098 2.37 6 x 104 
 thymic T cell selection  GO:0045061 6.97 6 x 10
4
 
 immune system development GO:0002520 1.74 0.002 
 leukocyte differentiation  GO:0002521 2.01 0.002 
Table 4. The top 5 most significantly enriched GO terms in genes 
associated with decreased and increased survival in NTM disease. 
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Module 
name 
Number 
of genes 
Correlation 
with mortality 
P 
value 
Relevant enriched GO terms 
darkorange 1,413 -0.5 0.01 
T cell receptor signalling pathway 
Thymic T cell selection,  
grey60 490 0.55 0.004 RAGE receptor binding 
White 71 0.46 0.02 None 
Table 5. Gene modules identified as significantly associated with 
decreased and increased survival in NTM disease. 
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Whole Blood Gene Expression in Pulmonary Non-tuberculous 
Mycobacterial Infection 
Steven A. Cowman, Joseph Jacob, David M. Hansell, Robert Wilson, William 
O. C. Cookson, Miriam F. Moffatt and Michael R. Loebinger 
ONLINE DATA SUPPLEMENT 
Page 46 of 59
Am
eri
ca
n J
ou
rna
l o
f R
es
pir
ato
ry 
Ce
ll a
nd
 M
ole
cu
lar
 B
iol
og
y 
Co
py
rig
ht 
© 
20
18
 A
me
ric
an
 Th
ora
cic
 S
oc
iet
y
Supplementary methods 
Inclusion and exclusion criteria: 
The criteria for inclusion or exclusion from the study are detailed in table E1. 
Inclusion Criteria Exclusion Criteria 
NTM Cases 
Clinical diagnosis of 
pulmonary NTM infection 
Age > 18 years 
Pregnancy 
Immunosuppression (other 
than oral corticosteroids) 
Malignancy 
Cystic fibrosis 
Active tuberculosis 
Underlying lung disease 
other than bronchiectasis or 
COPD 
Controls 
Bronchiectasis or COPD 
Age > 18 years 
Pregnancy 
Immunosuppression (other 
than oral corticosteroids) 
Malignancy 
Cystic fibrosis 
Fungal disease 
Active or past history of any 
mycobacterial disease 
Radiology suggestive of 
mycobacterial disease 
Table E1. Study Inclusion and exclusion criteria 
Sampling and assessment of studied subjects: 
The following procedures were performed for all study participants: structured 
clinical interview, administration of the St George’s Respiratory Questionnaire 
(SGRQ), measurement of height, weight and transcutaneous oxygen 
saturation, pulmonary function testing (spirometry, lung volumes by 
plethysmography and carbon monoxide transfer factor), peripheral venous 
blood sampling (for RNA extraction, full blood count and cell differential, urea 
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and creatine, electrolytes, liver function testing, bone profile, total serum 
vitamin D level and C-reactive protein (CRP) level), collection of 
spontaneously expectorated sputum (for phenol auramine microscopy, 
mycobacterial, bacterial and fungal culture), and high resolution CT thorax 
(unless done within previous 6 months). 
CT scoring: 
CT scoring was performed by a specialist radiologist with 5 years of 
experience in thoracic imaging, blinded to clinical details. For bronchiectasis 
extent, bronchiectasis severity, tree-in-bud opacification, nodules and 
consolidation, tertiles of the maximum possible score for each feature were 
used to categorise the features as mild, moderate or severe. For cavitating 
nodules, severe cavitation and aspergilloma scores for each feature were 
dichotomised as present or absent. As a measure of the overall severity of 
their radiological changes, composite CT scores were calculated for each 
participant by adding the individual scores for bronchiectasis extent, 
bronchiectasis severity, tree-in-bud opacification, nodules, consolidation, 
cavitating nodules, severe cavitation and aspergilloma. 
Gene expression analysis: 
RNA was isolated from peripheral blood using PAXgene RNA tubes (Becton, 
Dickinson and Company, NJ, USA) and extracted using the PAXgene Blood 
RNA Kit (PreAnalytiX, Hombrechtikon, Switzerland). Extracted RNA was 
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amplified to complementary DNA using the Ovation Pico WTA System V2 
(NuGEN Technologies, San Carlos, USA), then cDNA was fragmented and 
labelled using the Encore Biotin Module (NuGEN Technologies) and 
immediately hybridised to Affymetrix Human Gene 1.1 ST array plates and 
scanned using the GeneTitan instrument (Affymetrix, Santa Clara, USA). 
Samples were randomised prior to amplification and again prior to 
fragmentation, labelling and hybridisation. RNA and cDNA were quantified 
using the Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific, 
Waltham, USA) and RNA integrity was assessed using the 2100 Bioanalyzer 
and RNA 6000 Nano Kit (Agilent Technologies, Santa Clara, USA). 
Outliers were identified using the arrayQualityMetrics package version 3.18.0 
(1) in the R environment version 3.1.2. Any sample flagged as an outlier using 
any of the three criteria (distance between arrays, signal intensity boxplots or 
M-A plots) was removed. Raw probe level data from .CEL files passing quality 
control were summarised, quantile normalised and log2 transformed using the 
Affymetrix Power Tools package. Expression data were re-imported into R 
version 3.1.2 where all downstream analyses were performed. Low-expressed 
probes (those with expression level below the global median) and 
unannotated probes were removed. 
Differentially expressed genes were identified using Significance Analysis of 
Microarrays (SAM) applying a false discovery rate (FDR) of 5% for 
significance. The Benjamini-Hochberg correction for multiple testing was used 
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to correct the FDR. For further details of SAM methodology please see the 
original description by Tusher et al. (2). 
To investigate the possibility that differences in the use of systemic steroids or 
NTM treatment may be responsible for the difference in expression between 
NTM cases and controls, multiple linear modelling was performed in R version 
3.1.2. The expression of each of the genes differentially expressed between 
NTM cases and controls was the dependent variable and NTM disease, NTM 
treatment and systemic steroid use plus interaction terms as the explanatory 
variables. A P value of 0.05 was deemed significant. 
Gene ontology analyses were performed using the WebGestalt tool 
(http://www.webgestalt.org updated on 30/01/2013) using the Gene Ontology 
Consortium (GO) database version 1.2 (updated 11/11/2012) and the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) database (updated 
21/03/2011). These databases were used to identify groups of functionally 
related genes which are present within a larger set of genes (for example a 
set of differentially expressed genes, or a gene module identified by WGCNA) 
more than would be expected by chance, referred to as ‘enrichment’. All 
expressed genes were used as the reference set, the hypergeometric test 
was used to determine the significance of gene enrichment using the 
Benjamini-Hochberg correction for multiple testing. An adjusted P value of 
0.05 was deemed significant. For the analysis of enrichment with the 31-gene 
sarcoid signature the hypergeometric test was performed using R version 
3.1.2. 
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Weighted Gene Co-expression Gene Network Analysis (WCGNA) was 
performed using the WGCNA package (3) according to the authors’ 
recommendations. All expressed genes were used as the initial input and 
genes with high (top 33%) connectivity were then selected to form the 
topological overlap matrix, using a soft thresholding power of 12. Hierarchical 
clustering was then used on this matrix to identify gene modules using a 
minimum module size of 30, and modules with greater than 75% similarity 
were merged. Module eigengenes were calculated as the first principal 
component of gene expression in each module and then used to calculate the 
correlation between module expression and phenotypic traits. 
The expression data are available via the Gene Expression Omnibus 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE97298). 
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Supplementary results 
Recruitment: 
Subjects were recruited using the criteria detailed in table E1. The control 
group was composed solely of Caucasian subjects. To prevent differences in 
ethnicity between groups from confounding the analysis of gene expression, 
two pNTM subjects of Chinese and Asian ethnicity were excluded prior to 
analysis as suitable controls matched for ethnicity could not be found. 
Clinical data: 
The results of peripheral blood testing for study participants are detailed in 
table E2. 
Cases Controls 
Haemoglobin 13.46 (±1.56) 12.65 (±3.83) 
Platelets 264 (±112) 230 (±94) 
Total leucocyte count 8.16 (±2.42) 7.39 (±1.86) 
Neutrophils 5.57 (±2.14) 4.63 (±1.54) 
Lymphocytes 1.67 (±0.64) 1.95 (±0.62) 
Eosinophils 0.15 (±0.13) 0.17 (±0.1) 
Monocytes 0.73 (±0.3) 0.61 (±0.19) 
CRP 19.24 (±39) 6.74 (±8.61) 
Albumin 37.92 (±5.3) 40.26 (±3.91) 
Table E2. Blood results of study participants. Values are shown as mean ±
standard deviation.
CT scoring: 
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The mean composite CT score was 4.34 (standard deviation ±1.41) ranging 
from 2.33 to 6.5. Details of individual CT features are shown in table E3. 
CT feature 
Mean 
score 
(±SD) 
Score 
Number of subjects 
(%) 
Bronchiectasis extent 
1.72 
(±0.71) 
Low 7 (28%) 
Intermediate 8 (32%) 
High 10 (40%) 
Bronchiectasis severity 
0.96 
(±0.35) 
Mild 10 (40%) 
Moderate 15 (60%) 
Severe 0 
Tree-in-bud 
opacification 
0.68 
(±0.55) 
Mild 19 (76%) 
Moderate 6 (24%) 
Severe 0 
Nodules 
0.74 
(±0.55) 
Mild 20 (80%) 
Moderate 5 (20%) 
Severe 0 
Cavitating nodules 
0.11 
(±0.16) 
Absent 15 (60%) 
Present 10 (40%) 
Severe cavitation 
0.13 
(±0.23) 
Absent 17 (68%) 
Present 8 (32%) 
Aspergilloma 
0.03 
(±0.08) 
Absent 22 (88%) 
Present 3 (12%) 
Consolidation 
0.46 
(±0.46) 
Mild 22 (88%) 
Moderate 3 (12%) 
Severe 0 
Table E3. Scores for individual CT features in pNTM cases. SD = standard 
deviation. 
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Gene expression and NTM disease 
RNA extraction: 
The mean RNA yield per sample was 198 ng/μl (range 71.8 to 353 ng/μl). 
The mean RIN was 8.5 (range 7.1 to 9.3). 
Quality control: 
Five samples were identified as outliers using Array Quality Metrics (three 
cases, two controls). These samples were excluded, leaving 52 working 
samples for downstream analysis. 
Figure E1. Quantile-quantile plot for differences in gene expression between 
pNTM and controls calculated using SAM. Dotted lines indicate the value of δ 
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corresponding to an FDR of 5%, transcripts showing significant differential 
expression are shown in green. 
Table E4. Genes differentially expressed between pNTM cases and controls. 
See attached document for table. 
Table E5. GO analysis of genes differentially expressed between pNTM 
cases and controls 
See attached document for table. 
Table E6. Linear modelling of gene expression and NTM disease, NTM 
treatment and systemic steroid use. 
See attached document for table. 
Table E7. WGCNA gene modules for pNTM cases and controls 
See attached document for table. 
Table E8. GO analysis of WGCNA modules associated with pNTM 
See attached document for table. 
IFNG expression and clinical outcomes: 
The relationship between IFNG expression and individual CT features is 
shown in Figure E2. 
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Figure E2. IFNG expression and individual CT features. 
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Clinical measure Correlation coefficient P - value 
FEV1 (% predicted) 0.345 0.078 
FVC (% predicted) 0.342 0.080 
TLC (% predicted) -0.009 0.965 
TLCO (% predicted) 0.335 0.088 
KCO (% predicted) 0.203 0.310 
Serum albumin (g/L) -0.091 0.652 
Serum CRP (mg/L) -0.015 0.939 
Neutrophil count 
(cells x 109/L) 
0.037 0.855 
Table E9. Correlation between IFNG expression and clinical features in 
control subjects. 
Gene expression and survival in NTM disease: 
Table E10. Genes associated with survival in pNTM 
See attached document for table. 
Table E11. GO analysis of genes associated with decreased survival in pNTM 
See attached document for table. 
Table E12. GO analysis of genes associated with increased survival in pNTM 
See attached document for table. 
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Figure E3. Quantile-quantile plot for gene expression and survival in pNTM 
cases calculated using SAM. Dotted lines indicate the value of δ 
corresponding to an FDR of 5%. Transcripts significantly associated with 
increased and decreased mortality are shown in red and green, respectively. 
Table E13. WGCNA gene modules for pNTM cases 
See attached document for table. 
Table E14. GO analysis of WGCNA modules associated with survival in 
pNTM 
See attached document for table. 
Supplementary references 
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